Soluble stem cell factor receptor (CD 117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: Relationships to disease severity and bone marrow pathology

Blood

Volumn 96, Issue 4, 2000, Pages 1267-1273

  Akin, C ^a   Schwartz, L B ^a   Kitoh, T ^a   Obayashi, H ^a   Worobec, A S ^a   Scott, L M ^a   Metcalfe, D D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ADULT; AGED; ALPHA CHAIN; ARTICLE; BLOOD LEVEL; BONE MARROW BIOPSY; BONE MARROW DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL;

EID: 0034663031     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1267.h8001267a_1267_1273     Document Type: Article

References (45)

1. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
2. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
3. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
4. Analysis of plasma histamine levels in patients with mast cell disorders
5. Increased production of prostaglandin D2 in patients with systemic mastocytosis
6. Increased urinary methylimidazoleacetic acid (MelmAA) as an indicator of systemic mastocytosis
7. The potential clinical utility of serum alpha-protryptase levels
8. Tryptase levels as an indicator of mastcell activation in systemic anaphylaxis and mastocytosis
9. Recurrent idiopathic anaphylaxis
10. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: Demonstration of elevated levels in patients with disorders of systemic mast cell activation
11. Bone marrow findings in systemic mastocytosis
12. Significance of systemic mast cell disease with associated hematologic disorders
13. Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis
14. Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia
15. Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders
16. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease
17. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival
18. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy
19. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis
20. Conclusions
21. Significance of stem cell factor and soluble KIT in patients with systemic lupus erythematosus
22. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
23. Soluble receptors in human disease
24. Systemic mast cell disease: Analysis of 58 cases and literature review
25. Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications
26. Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines
27. Elevated SCF levels in the serum of patients with chronic renal failure
28. Soluble c-kit levels in acute GVHD after allogeneic bone marrow transplantation
29. Low levels of serum soluble c-kit relates to delayed engraftment after bone marrow transplantation
30. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer
31. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation
32. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis
33. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis
34. Soluble IL-2 receptor in rheumatoid arthritis: Correlation with disease activity, IL-1 and IL-2 inhibition
35. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis
36. Serum levels of soluble Tac peptide in acute and chronic hepatitis B virus infection
37. Soluble IL-2 receptor in AIDS: Correlation of its serum level with the classification of HIV-induced diseases and its characterization
38. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: Relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity
39. Serum levels of IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases
40. Characterization of proliferative responses and cytokine mRNA profiles induced by Vespula venom in patients with severe reactions to wasp stings
41. Concomitant augmentation of CD4+ CD45R+ suppressor/inducer subset and diminution of CD4+ CDw29+ helper/inducer subset during rush hyposensitization in hymenoptera venom allergy
42. Serum stem cell factor levels in patients with aplastic anemia
43. Levels of soluble stem cell factor in serum of patients with aplastic anemia
44. Serum stem cell factor concentration in patients with myelodysplastic syndromes
45. Soluble kit receptor in human serum